MedTrace Logo

A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas

NCT02104310 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-04-06

No results posted yet for this study

Summary

For most brain tumors, radiation treatment is guided by a Magnetic Resonance Imaging (MRI) scan. In this study, information from a special scan, called a Positron Emission Tomography/ Computed Tomography (PET/CT) scan using an amino acid called Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) will also be used. This type of scan has shown promise in being able to better distinguish tumor from normal brain tissue and may help to more accurately plan radiation treatment. This type of scan can also assist the radiation oncologist in identifying the most aggressive regions of the tumor. The goal of this study is to compare the 18F-DOPA PET/CT scan with the MRI scan for identifying where the disease is that needs to be treated with radiation.

Conditions

  • Malignant Glioma

Interventions

DRUG

Fluorine-18-L-dihydroxyphenylalanine

5 millicuries ± 10%; Intravenous injection; 1 time

Sponsors & Collaborators

  • Brains Together for the Cure

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Nadia N Laack, MD · Mayo Clinic

  • Debra Brinkmann, PhD · Mayo Clinic

  • Deanna Pafundi, PhD · Mayo Clinic

Eligibility

Min Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-08
Primary Completion
2021-03-26
Completion
2031-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02104310 on ClinicalTrials.gov